-+ 0.00%
-+ 0.00%
-+ 0.00%

Stoke Therapeutics Q4 2024 GAAP EPS $(0.18) Beats $(0.53) Estimate, Sales $22.60M Beat $4.28M Estimate

Benzinga·03/18/2025 11:30:18
Listen to the news
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.53) by 66.04 percent. This is a 70 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $22.60 million which beat the analyst consensus estimate of $4.28 million by 428.04 percent. This is a 706.85 percent increase over sales of $2.80 million the same period last year.